Clinical trials: open to volunteers, sponsored by AstraZeneca
Hepatic Impairment
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.
- Trial name
- NCT07546760
- Testing
- AZD6234, AZD9550
- Where
- 4 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants
The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and…
- Trial name
- NCT07290283
- Testing
- AZD3974
- Where
- 2 sites in United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants, Obesity
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or…
- Trial name
- NCT07511205
- Testing
- AZD1043
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers
The main purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) of AZD4916 in healthy adult participants.
- Trial name
- NCT06951880
- Testing
- AZD4916
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants
The purpose of the study is to assess the pharmacokinetics (PK) of AZD4144 when administered alone and in combination with itraconazole in healthy participants.
- Trial name
- NCT07685600
- Testing
- AZD4144, Itraconazole
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Human Metapneumovirus Infection
Study of Safety and PK of AZD0543 in Healthy Adults
The purpose of this study is to assess the safety and PK of AZD0543 compared to placebo in healthy adults 18 to 55 years of age. AZD0543 or placebo will be administered as single IM or IV dose.
- Trial name
- NCT07824622
- Testing
- AZD0543
- Where
- 2 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.
- Trial name
- NCT07723833
- Testing
- Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954
This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth.
- Trial name
- NCT07812077
- Testing
- [14C]AZD4954 Oral Solution, AZD4954 film-coated tablet, [14C]AZD4954 Solution for Infusion
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Moderate Hepatic Impairment
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment and participants with normal hepatic function (as control).
- Trial name
- NCT07343960
- Testing
- Capivasertib
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hepatic Impairment
A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144
This Phase I, open-label, parallel group study will investigate the single oral dose PK, safety, and tolerability of AZD4144 to male and female participants with mild, moderate, and severe hepatic impairment compared to matched…
- Trial name
- NCT07783308
- Testing
- AZD4144
- Where
- 4 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of…
- Trial name
- NCT06419413
- Where
- 21 sites in China
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV)…
- Trial name
- NCT07024823
- Testing
- AZD4248
- Where
- 5 sites in United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- AstraZeneca